Hypothesis: Chronic metabolic optimization via acarbose may reduce specific dimensions of conscious experience—including spontaneous cognition, mind-wandering, and creative divergent thinking—by shifting neural dynamics away from metabolically costly critical regimes necessary for high-dimensional signal integration.

Background and Gaps: ITP studies show acarbose extends median lifespan by 28-34% in mice through alpha-glucosidase inhibition, GLP-1 elevation, and gut microbiota remodeling [https://gethealthspan.com/science/article/acarbose-and-rapamycin-longevity][https://pmc.ncbi.nlm.nih.gov/articles/PMC4620230/][https://pmc.ncbi.nlm.nih.gov/articles/PMC9286917/]. Yet no one has asked whether such systemic metabolic changes affect the brain's computational architecture or the phenomenological properties of consciousness. The brain uses roughly 20% of resting metabolic energy despite making up only 2% of body mass—an apparent inefficiency that persists even during sleep reduction, suggesting evolutionary constraint rather than poor design.

Novel Mechanistic Framework: This apparent inefficiency likely serves a thermodynamic purpose: maintaining neural circuits at or near criticality requires energy beyond the minimum needed for pure signal propagation. This "metabolic slack" enables the noise-driven, high-dimensional burst activity patterns (avalanche dynamics) associated with conscious perception and spontaneous thought. By reducing postprandial glucose excursions and improving insulin sensitivity, acarbose may optimize the brain's fuel supply in ways that lower metabolic variability—potentially constraining the fluctuations necessary for critical-state dynamics.

Testable Predictions:

1. Human Cognitive Assessment: Adults given acarbose (standard diabetes prevention dosing) for 12+ weeks will perform worse on divergent thinking tasks and report less mind-wandering compared to placebo, while maintaining or improving convergent processing speed.
2. Neural Correlates: Functional MRI during resting state will show reduced default mode network (DMN) connectivity and decreased avalanche-like BOLD signal dynamics in acarbose-treated subjects.
3. Animal Model: Acarbose-treated mice will explore novel environments less and show reduced hippocampal sharp-wave ripple density during rest—neural signatures associated with spontaneous cognition and memory consolidation.
4. Dose-Response: Cognitive effects should track the degree of metabolic optimization (measured by reduced glucose variability and improved insulin sensitivity), providing a mechanistic link.

Falsifiability: This hypothesis is falsifiable if acarbose-treated subjects show no cognitive changes across domains, or if cognitive improvements accompany metabolic optimization—contradicting the proposed trade-off between efficiency and consciousness richness.

Why This Matters: If metabolic optimization necessarily constrains consciousness, we'd face a fundamental limit on longevity interventions: we might extend biological lifespan while inadvertently diminishing the phenomenological richness of the life being extended. This framework bridges biogerontology, neuroscience of consciousness, and information theory under a single testable premise.